RU2013158861A - Способы и композиции для предсказания активности модулятора ретиноидного х-рецептора - Google Patents
Способы и композиции для предсказания активности модулятора ретиноидного х-рецептора Download PDFInfo
- Publication number
- RU2013158861A RU2013158861A RU2013158861/10A RU2013158861A RU2013158861A RU 2013158861 A RU2013158861 A RU 2013158861A RU 2013158861/10 A RU2013158861/10 A RU 2013158861/10A RU 2013158861 A RU2013158861 A RU 2013158861A RU 2013158861 A RU2013158861 A RU 2013158861A
- Authority
- RU
- Russia
- Prior art keywords
- panel
- molecules
- biomarkers
- snps
- analysis
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 6
- 102000034527 Retinoid X Receptors Human genes 0.000 title claims 3
- 108010038912 Retinoid X Receptors Proteins 0.000 title claims 3
- 229940075993 receptor modulator Drugs 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title 1
- 239000000090 biomarker Substances 0.000 claims abstract 16
- 230000000295 complement effect Effects 0.000 claims abstract 10
- 238000004458 analytical method Methods 0.000 claims abstract 9
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract 8
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims abstract 6
- 230000008878 coupling Effects 0.000 claims abstract 6
- 238000010168 coupling process Methods 0.000 claims abstract 6
- 238000005859 coupling reaction Methods 0.000 claims abstract 6
- 229920001184 polypeptide Polymers 0.000 claims abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract 3
- 239000002773 nucleotide Substances 0.000 claims abstract 3
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 3
- 102000054765 polymorphisms of proteins Human genes 0.000 claims abstract 2
- 239000000758 substrate Substances 0.000 claims abstract 2
- 238000002405 diagnostic procedure Methods 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 102100038495 Bile acid receptor Human genes 0.000 claims 2
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 102000004311 liver X receptors Human genes 0.000 claims 2
- 108090000865 liver X receptors Proteins 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000005251 capillar electrophoresis Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 238000004925 denaturation Methods 0.000 claims 1
- 230000036425 denaturation Effects 0.000 claims 1
- 239000003596 drug target Substances 0.000 claims 1
- 238000000840 electrochemical analysis Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000001502 gel electrophoresis Methods 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 238000011285 therapeutic regimen Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- High Energy & Nuclear Physics (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Databases & Information Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161494773P | 2011-06-08 | 2011-06-08 | |
| US61/494,773 | 2011-06-08 | ||
| PCT/US2012/041379 WO2012170704A2 (en) | 2011-06-08 | 2012-06-07 | Methods and compositions of predicting activity of retinoid x receptor modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013158861A true RU2013158861A (ru) | 2015-07-20 |
Family
ID=47296742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013158861/10A RU2013158861A (ru) | 2011-06-08 | 2012-06-07 | Способы и композиции для предсказания активности модулятора ретиноидного х-рецептора |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10202652B2 (OSRAM) |
| EP (1) | EP2718486A4 (OSRAM) |
| JP (1) | JP2014524735A (OSRAM) |
| KR (1) | KR20140039278A (OSRAM) |
| CN (1) | CN103649386B (OSRAM) |
| AU (1) | AU2012267877B2 (OSRAM) |
| BR (1) | BR112013031221A2 (OSRAM) |
| CA (1) | CA2838207A1 (OSRAM) |
| MX (1) | MX2013014437A (OSRAM) |
| RU (1) | RU2013158861A (OSRAM) |
| SG (1) | SG195191A1 (OSRAM) |
| WO (1) | WO2012170704A2 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| WO2014085365A2 (en) | 2012-11-28 | 2014-06-05 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| IL292303A (en) | 2012-12-27 | 2022-06-01 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US9782075B2 (en) * | 2013-03-15 | 2017-10-10 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
| US11089959B2 (en) * | 2013-03-15 | 2021-08-17 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
| SG11201602870YA (en) | 2013-10-28 | 2016-05-30 | Ngm Biopharmaceuticals Inc | Cancer models and associated methods |
| US20150147339A1 (en) * | 2013-11-15 | 2015-05-28 | Psma Development Company, Llc | Biomarkers for psma targeted therapy for prostate cancer |
| PL3097122T3 (pl) | 2014-01-24 | 2020-10-19 | Ngm Biopharmaceuticals, Inc. | Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania |
| WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
| WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| CN104131102B (zh) * | 2014-08-07 | 2016-06-15 | 马飞 | 一种判断nsclc患者对吉非替尼治疗反应性的试剂盒 |
| WO2016065106A1 (en) | 2014-10-23 | 2016-04-28 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
| WO2016073855A1 (en) * | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| AU2016353988B2 (en) | 2015-11-09 | 2019-09-26 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| WO2018039557A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| JOP20190025A1 (ar) * | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | طرق وتركيبة لتوقع نشاط إنزاستورين |
| JP7267198B2 (ja) * | 2017-08-31 | 2023-05-01 | 株式会社 資生堂 | レチノイドの副作用に対する感受性の決定方法 |
| CN108504733A (zh) * | 2017-11-29 | 2018-09-07 | 中山拓普基因科技有限公司 | 肿瘤个体化化疗用药指导基因snp位点检测组合物 |
| KR102169699B1 (ko) * | 2019-12-27 | 2020-10-23 | 주식회사 클리노믹스 | 유전자 검사를 위한 맞춤형 유전자칩 및 이의 제작 방법 |
| EP4106872A4 (en) | 2020-03-06 | 2024-04-10 | Denovo Biopharma LLC | Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters |
| KR20250118433A (ko) * | 2024-01-30 | 2025-08-06 | 서울대학교산학협력단 | 알츠하이머병 발병 위험도 예측을 위한 레이 복잡도 복사 점수 저하와 관련이 있는 단일염기다형성 마커 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007038670A2 (en) * | 2005-09-30 | 2007-04-05 | Perlegen Sciences, Inc. | Methods and compositions for screening and treatment of disorders of blood glucose regulation |
| JP2009510114A (ja) * | 2005-09-30 | 2009-03-12 | ビテ ファーマシューティカルズ， インコーポレイテッド | 特定のｒｘｒアゴニストによる癌治療 |
| US20080299125A1 (en) | 2006-06-05 | 2008-12-04 | Perlegen Sciences, Inc. | Genetic basis of treatment response in depression patients |
| WO2009134774A1 (en) | 2008-04-28 | 2009-11-05 | Expression Analysis | Methods and systems for simultaneous allelic contrast and copy number association in genome-wide association studies |
| EP2451455A4 (en) | 2009-07-10 | 2013-01-16 | Univ Case Western Reserve | RXR AGONIST COMPOUNDS AND METHODS |
| CA2779223A1 (en) * | 2009-10-27 | 2011-05-12 | Caris Mpi, Inc. | Molecular profiling for personalized medicine |
| US7790396B1 (en) | 2009-12-23 | 2010-09-07 | Suregene, Llc | Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype |
-
2012
- 2012-06-07 CA CA2838207A patent/CA2838207A1/en not_active Abandoned
- 2012-06-07 KR KR1020147000545A patent/KR20140039278A/ko not_active Withdrawn
- 2012-06-07 WO PCT/US2012/041379 patent/WO2012170704A2/en not_active Ceased
- 2012-06-07 SG SG2013087861A patent/SG195191A1/en unknown
- 2012-06-07 RU RU2013158861/10A patent/RU2013158861A/ru not_active Application Discontinuation
- 2012-06-07 MX MX2013014437A patent/MX2013014437A/es not_active Application Discontinuation
- 2012-06-07 US US14/124,668 patent/US10202652B2/en active Active
- 2012-06-07 AU AU2012267877A patent/AU2012267877B2/en not_active Ceased
- 2012-06-07 CN CN201280027212.8A patent/CN103649386B/zh not_active Expired - Fee Related
- 2012-06-07 EP EP12797326.1A patent/EP2718486A4/en not_active Ceased
- 2012-06-07 JP JP2014514846A patent/JP2014524735A/ja active Pending
- 2012-06-07 BR BR112013031221A patent/BR112013031221A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012267877A1 (en) | 2014-01-23 |
| EP2718486A2 (en) | 2014-04-16 |
| CN103649386A (zh) | 2014-03-19 |
| SG195191A1 (en) | 2013-12-30 |
| MX2013014437A (es) | 2015-03-20 |
| BR112013031221A2 (pt) | 2017-01-24 |
| CN103649386B (zh) | 2015-12-23 |
| US10202652B2 (en) | 2019-02-12 |
| AU2012267877B2 (en) | 2015-12-24 |
| US20150368720A1 (en) | 2015-12-24 |
| KR20140039278A (ko) | 2014-04-01 |
| JP2014524735A (ja) | 2014-09-25 |
| WO2012170704A3 (en) | 2013-01-31 |
| WO2012170704A2 (en) | 2012-12-13 |
| EP2718486A4 (en) | 2014-12-31 |
| CA2838207A1 (en) | 2012-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014524735A5 (OSRAM) | ||
| Shendure et al. | DNA sequencing at 40: past, present and future | |
| Hosomichi et al. | The impact of next-generation sequencing technologies on HLA research | |
| Druley et al. | Quantification of rare allelic variants from pooled genomic DNA | |
| Prasad et al. | A discovery resource of rare copy number variations in individuals with autism spectrum disorder | |
| Hodges et al. | Genome-wide in situ exon capture for selective resequencing | |
| García-Giménez et al. | Epigenetic biomarkers: A new perspective in laboratory diagnostics | |
| Hameed et al. | Haplotypes and variable position detection in the mitochondrial DNA coding region encompassing nucleotide positions 10,716–11,184 | |
| Schweiger et al. | The power of NGS technologies to delineate the genome organization in cancer: from mutations to structural variations and epigenetic alterations | |
| Kim et al. | Recent omics technologies and their emerging applications for personalised medicine | |
| Zhang et al. | Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data | |
| Kriegsmann et al. | Detection of KRAS, NRAS and BRAF by mass spectrometry-a sensitive, reliable, fast and cost-effective technique | |
| Faita et al. | Next generation sequencing in cardiovascular diseases | |
| JP2014524735A (ja) | レチノイドｘレセプターの調節因子の活性を予測する方法および組成物 | |
| Huang et al. | Efficient SNP discovery by combining microarray and lab-on-a-chip data for animal breeding and selection | |
| Yu et al. | Lessons and applications of omics research in diabetes epidemiology | |
| Biswas et al. | Next generation sequencing in cardiomyopathy: towards personalized genomics and medicine | |
| RU2009127735A (ru) | Определение предрасположенности к раку путем идентификации генотипических комбинаций специфичных вариантов генов cyp1b1, brca2 и снек2 | |
| Ortiz et al. | Generic platform for the multiplexed targeted electrochemical detection of osteoporosis-associated single nucleotide polymorphisms using recombinase polymerase solid-phase primer elongation and ferrocene-modified nucleoside triphosphates | |
| Greenbaum et al. | Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3′-untranslated region | |
| Adams et al. | Global mutational profiling of formalin-fixed human colon cancers from a pathology archive | |
| Newman et al. | Sensitive quantitative analysis of murine LINE1 DNA methylation using high resolution melt analysis | |
| Mamedov et al. | A new set of markers for human identification based on 32 polymorphic Alu insertions | |
| Nakakura et al. | HLA-B* 39: 01: 01 is a novel risk factor for antithyroid drug-induced agranulocytosis in Japanese population | |
| Bayés et al. | Applications of second generation sequencing technologies in complex disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20161031 |